Castle Biosciences Ranked Third Among 2023 Top Workplaces in the Healthcare Industry
19 Setembro 2023 - 8:00AM
Business Wire
National award recognizes Castle’s strong
culture and employee engagement
Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving
health through innovative tests that guide patient care, today
announced that it has earned a Top Workplaces National Industry
Award, ranking third among 84 Top Workplaces in the healthcare
industry. Castle has earned several additional Top Workplace awards
this year, including Top Workplaces USA and Arizona Top Workplace
awards, both for the second consecutive year, as well as five
Culture Excellence Awards for Innovation, Work-Life Flexibility,
Compensation & Benefits, Leadership and Purpose &
Values.
“Being recognized as a Top Workplace in the healthcare industry
and earning a top ranking nationally is a humbling achievement that
we are most proud of,” said Derek Maetzold, president and chief
executive officer at Castle Biosciences. “People come first at
Castle, and our unique culture reflects that mindset. We credit
this award and our ongoing success to our dedicated employees, who
are committed to helping us empower clinicians and patients with
personalized information that can inform important healthcare
decisions.”
“Earning a Top Workplaces award is a badge of honor for
companies, especially because it comes authentically from their
employees,” said Eric Rubino, Energage chief executive officer.
“That's something to be proud of. In today's market, leaders must
ensure they’re allowing employees to have a voice and be heard.
That's paramount. Top Workplaces do this, and it pays
dividends.”
View winners of the 2023 Top Workplaces in Healthcare here.
About Castle Biosciences
Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics
company improving health through innovative tests that guide
patient care. The Company aims to transform disease management by
keeping people first: patients, clinicians, employees and
investors.
Castle’s current portfolio consists of tests for skin cancers,
uveal melanoma, Barrett’s esophagus and mental health conditions.
Additionally, the Company has active research and development
programs for tests in other diseases with high clinical need,
including its test in development to predict systemic therapy
response in patients with moderate-to-severe psoriasis, atopic
dermatitis and related conditions. To learn more, please visit
www.CastleBiosciences.com and connect with us on LinkedIn,
Facebook, Twitter and Instagram.
DecisionDx-Melanoma, DecisionDx-CMSeq, DecisionDx-SCC, MyPath
Melanoma, DecisionDx-UM, DecisionDx-PRAME, DecisionDx-UMSeq,
TissueCypher and IDgenetix are trademarks of Castle Biosciences,
Inc.
About Energage
Making the world a better place to work together.™
Energage is a purpose-driven company that helps organizations
turn employee feedback into useful business intelligence and
credible employer recognition through Top Workplaces. Built on 16
years of culture research and the results from 27 million employees
surveyed across more than 70,000 organizations, Energage delivers
the most accurate competitive benchmark available. With access to a
unique combination of patented analytic tools and expert guidance,
Energage customers lead the competition with an engaged workforce
and an opportunity to gain recognition for their people-first
approach to culture. For more information or to nominate your
organization, visit energage.com or topworkplaces.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230919117952/en/
Investor Contact: Camilla Zuckero
czuckero@castlebiosciences.com
Media Contact: Allison Marshall
amarshall@castlebiosciences.com
Castle Biosciences (NASDAQ:CSTL)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Castle Biosciences (NASDAQ:CSTL)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024